Vedolizumab-4030: Understand the Outcomes of Inflammatory Bowel Disease (IBD) Patients Treated with Biologics in Taiwan – A Decentralized Vedolizumab and Biologic Agents Core Assessments in IBD Collaboration

Study identification

• EU PAS number:
  EUPAS48289
• Study ID:
  50648
• Official title and acronym:
  Vedolizumab-4030: Understand the Outcomes of Inflammatory Bowel Disease (IBD) Patients Treated with Biologics in Taiwan – A Decentralized Vedolizumab and Biologic Agents Core Assessments in IBD Collaboration
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study status:
  Finalised

Research institutions and networks

Institutions

Takeda

Chang Gung Medical Foundation, Linkou Taoyuan City, China Medical University Hospital Taichung City, National Taiwan University Hospital Taipei, Taichung Veterans General Hospital Taichung City

Study timelines

Date when funding contract was signed

Planned: 03/03/2020

Actual: 03/03/2020

Study start date

Planned: 27/05/2021

Actual: 27/05/2021

Date of final study report

Planned: 31/03/2023

Actual: 08/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable